Sea Crest Health Care Center

Celebrating a full spectrum of restorative and nursing care

Need a New Hip? Check the Joint Registry First

806,000 hip and knee implants were performed in the US in 2007 – that’s double the amount done a decade earlier. However, a 2007 study demonstrates that 7% of Medicare patients who underwent a hip replacement required another replacement hip within seven and a half years.  That number, small as it sounds, translates into thousands of patients who eventually need a “do over”. A joint surgery involves risk, pain, convalescence, rehab and medical expenses; no one wants to go through that more than once if necessary.

A National Joint Replacement Registry helps reduce the rate of failed procedures by keeping a database of information that keys in surgeons to problematic implants, and provides insight as to how to avoid mess ups. According to Dr. Daniel Berry, chief of orthopedic surgery at the Mayo Clinic in Rochester, Minn,  “Every country that has developed a registry has been able to reduce failure rates significantly.”  Sweden is one case in point.

The newly formed American Joint Replacement Registry is still in its nascent stage and has started collecting data. Its goal is to improve the quality, outcomes, and cost-effectiveness of total joint replacement (TJR) surgeries through the achievement of four objectives:

1. Establish an infrastructure and a uniform system for the collecting device information and monitoring outcomes of TJR throughout the U.S.;

2. Identify patients who may need follow-up evaluation thereby increasing patient safety;

3. Create real-time survivorship curve in order to detect poorly performing implants;

4. Establish a uniform system that can be used to define the epidemiology of TJR for outcomes research to improve the quality and outcomes of patient care.

Until we have access to solid facts from the U.S. Registry, there are some proactive steps you can take if you are in the market for a new joint.

– Go with a highly experienced surgeon in a busy hospital; don’t look for the best deal. Ask for recommendations. A 2004 study published in The Journal of Bone and Joint Surgery found that patients receiving knee replacements from doctors who performed more than 50 of the procedures a year had fewer complications than patients whose surgeons did 12 procedures or fewer a year.

A similar trend was documented with hospital volume. Patients at hospitals that performed more than 200 knee replacements a year fared better than patients at hospitals that performed 25 or fewer.

– A joint replacement is not for everyone. Some arthritic problems are better served with medication, and surgery may be too risky for those who have uncontrolled high blood pressure or another serious chronic condition.

– Research the joint implant that your surgeon recommends. Find out how well it has performed in others and if there are known complications. Some implants are somewhat controversial and may cause tissue and bone damage; newer doesn’t necessarily mean better. If the hospital has its own registry, ask to review the data.

– Educate yourself as to what the surgery entails. The American Academy of Orthopaedic Surgeon’s patient information Web site, orthoinfo.org is very helpful.

– Prepare your recovery in advance. Arrange for the necessary support upon your return home, and make sure you have all the help you need. It is crucial not to overexert yourself during your initial healing period.

Tags: , , , , ,
July 8, 2010 - 10:26 AM No Comments

Optimistic Advances in Search for an Alzheimer’s Miracle Drug

By Neil Bekker

At the recent International Conference on Alzheimer’s Disease in Chicago, some interesting discoveries in Alzheimer’s research were presented.

Claude Wischik, Ph.D., of the University of Aberdeen in Scotland and founder and chairman of TauRx Therapeutics presented the findings of his 84 week study, whereas 321 seniors were given a daily capsule of Rember, which stopped their cognitive decline by an astonishing rate of 81%. Rember is a a new formulation of methylene blue (Urolene Blue), a drug  used to combat urinary-tract infections in the past, and was developed to  target the protein “tangles” in the brain, stopping new tangles from forming and loosening those that already exist. This theory counters the accepted amyloid hypothesis, which contends that the buildup of amyloid plaque  (the sticky brain-clogging masses) in the brain is the main mechanism of Alzheimer’s disease.

Others believe that both amyloid and tangles, also called tau, are important factors in Alzheimer’s and that the ideal treatment would be a combination of medication that targeted both.

Another interesting presentation was given by researchers from Mt. Sinai School of Medicine on an interesting link between alzheimer’s and insulin. Alzheimer’s patients with diabetes who took insulin plus another anti-diabetes medication to control blood sugar, had 80% fewer amyloid plaques than those who were not diabetic. The drugs seem to regulate the brain’s communication network of insulin receptors, which goes awry in the Alzheimer’s brain, while at the same time clearing away the damaging plaques.

New screening tests to identify Alzheimer’s patients in the earlier stages before their brain deteriorates too much – was another innovation presented. By identifying patients by the specific type of brain buildup — plaques versus tangles — that they are suffering from, doctors can utilize the more effective therapies for each individual.

Tags: , , , , , , , , , , , , , , , , , , ,
August 1, 2008 - 8:11 AM No Comments